Quote | Ventyx Biosciences Inc. (NASDAQ:VTYX)
Last: | $4.02 |
---|---|
Change Percent: | -10.27% |
Open: | $4.84 |
Close: | $4.48 |
High: | $5.01 |
Low: | $3.8409 |
Volume: | 534,653 |
Last Trade Date Time: | 05/10/2024 03:00:00 am |
News | Ventyx Biosciences Inc. (NASDAQ:VTYX)
2024-05-09 16:04:01 ET More on Ventyx Biosciences Ventyx Pivots To Obesity Amid Transformation Ventyx Biosciences drops 3%, stockholders to sell ~11.17M shares Ventyx rebounds as Oppenheimer upgrades after pipeline updates Seeking Alpha’s Quant Rating ...
Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson’s disease and in participants with obesity with certain additional cardiovascular risk factors Cash, cash equivalents and marketable securities of $302.6 million as ...
Message Board Posts | Ventyx Biosciences Inc. (NASDAQ:VTYX)
Subject | By | Source | When |
---|---|---|---|
just the news we needed | DewDiligence | investorshub | 07/02/2023 2:16:23 AM |
Price now up | crudeoil24 | investorshub | 06/13/2023 7:26:13 PM |
just the news we needed | crudeoil24 | investorshub | 06/12/2023 8:45:23 AM |
Ventyx Biosciences, Inc. (Nasdaq: $VTYX) (Ventyx), a clinical-stage | crudeoil24 | investorshub | 09/19/2022 4:15:16 PM |
znewcar1: VTYX 64% v15,6M c38.11 f50,9M H41.29 ML16.91 off the 20dma@19.73 | znewcar1 | investorshangout | 09/13/2022 1:57:39 AM |
News, Short Squeeze, Breakout and More Instantly...
Ventyx Biosciences Inc. Company Name:
VTYX Stock Symbol:
NASDAQ Market:
Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson’s disease and in participants with obesity with certain additional cardiovascular risk factors Cash, cash equivalents and marketable securities of $302.6 million as ...
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focus...
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced th...